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INTRODUCTION 
Varicella-Zoster virus (VZV) is the etiologic agent of two 
diseases, Varicella (Chicken pox) and Zoster (Shingles). 
Varicella which occurs after the initial encounter with 
Varicella Zoster virus, is a disease manifested by a pruritic rash 
accompanied by fever and other systemic signs and symptoms that 
are usually mild to moderate nature. 
Most often Varicella is a self-limited infection of childhood. 
Zoster is mainly a disease of adults. A prerequisite for 
developing zoster is a prior episode of Varicella, which on occasion 
may have been sub-clinical. 
During Varicella, VZV establishes latent infection in sensory 
nerve ganglion. Zoster results when the latent virus reactivates and 
returns from the ganglion to infect the skin. 
Most often VZV reactivates in the settings of relative 
immunologic compromise, as occurs with aging, or following 
disease or various therapies, such as steroids, cancer chemotherapy 
transplantation and irradiation. 
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The diagnosis is clinical: very few other diseases mimic 
herpes zoster, especially in the localization of the rash, which is 
otherwise quite similar in appearance and initial effect of that of 
poison oak or poison ivy. 
In case of doubt, diagnostic tests can be performed. Such lab 
tests may be necessary because, depending on the affected sensory 
nerve, the pain that is experienced before the onset of rash may be 
misdiagnosed as pleurisy, myocardial infarction, appendicitis or 
migraine headache. 
A physician can take a viral culture of a fresh lesion, (or) 
perform a microscopic examination of the blister base material 
called a Tzanck preparation. 
In a complete blood count, there may be an elevated number 
of white blood cells, which is an indirect sign of infection. There 
may also be a rise in the antibody to the virus, which could also give 
indication to the virus. 
Currently, there is no complete cure available for herpes 
zoster, nor a treatment to effectively eliminate the virus from the 
body. However, there are some treatments that can mitigate the 
length of the disease and alleviate certain side effects. 
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REVIEW OF LITERATURE 
HISTORICAL OVERVIEW: 
Varicella was distinguished clinically from small pox in the 
mid 18th century. The origin of the name chickenpox is uncertain, 
but it may have been derived from the French “pois chiche” or chick 
pea or from the farmyard fowl (in old English cicen and Middle 
High German kuchen). The name ‘shingles’ is derived from the 
Latin word ‘cingulus’ meanings girdle (Zaia, 1981) 
Herpes is derived from the Greek word meaning to “creep”. 
Zoster is the Greek word meaning “girdle or belt”. 
In 1875, Steiner successfully transmitted VZV by inoculation 
of the vesicular fluid from a person suffering from chickenpox to - 
“volunteer”1. 
The delineation of the link between Varicella and zoster is of 
virologic, medical and historical interest. A connection was 
postulated in 1888 by Von Bokay2 who recognized that cases of 
Varicella often occurred following exposure to a patient with zoster. 
Kundratitz in 19253 showed that the inoculation of vesicular fluid 
from patients with herpes zoster into susceptible person resulted in 
chickenpox. Similar observations were reported by Brunsguard and others. 
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In 1943 Garland4 suggested that herpes zoster was the 
consequence of the reaction of latent VZV. 
Since early in the 20th century, similarities in the  
histo-pathologic feature of skin lesions and in epidemiologic and 
immunologic studies indicated that Varicella and herpes zoster 
were caused by the same agent5. 
Tyzzer6 described the histo-pathologic features of skin lesions 
resulting from VZV injections and noted the appearance of 
intranuclear inclusions and multinucleated giant cells. 
The histopathologic descriptions were amplified by Lipschutz 
in 19217 for herpes zoster. 
Isolation of VZV in 1958 permitted a definition of the biology 
of this virus8. 
By 1958, Weller and colleagues8 had been able to establish 
that there were neither biologic nor immunologic differences  
between the viral agents isolated from patients with chickenpox 
and herpes zoster. 
Viral DNA from a patient with chickenpox who subsequently 
developed herpes zoster was examined by restriction endonuclease 
analysis and the molecular identity of these two viruses was 
verified. 
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Hope-Simpson10 was the first to recognize the importance of 
the immune system in controlling manifestations of zoster. He 
postulated that zoster resulted when humoral immunity to VZV 
wanes in the years and decades after Varicella. 
More recently the importance of declining cellular rather 
than humoral immunity to VZV was recognized in the pathogenesis of 
zoster10. 
Cyto-diagnosis of herpes infection by smear taken from the base 
of a blister reveals the characteristic cytopathic effects of herpetic 
infection and multinucleated giant cells were introduced by Tzanck in 
194711. 
Before the availability of antiviral drug, oral pancreatic 
enzyme therapy in shingles was used in some countries and later 
subjected to clinical and scientific research12. A large scale study, 
using an oral preparation of such enzymes has shown promising 
results. 
  Antiviral drugs Acyclovir was discovered in 1974. Preclinical 
investigation brought the drugs to clinical trials in 1977 and the 
first form of drug (topical) was available in 198213.  
A live attenuated vaccine using the same strain (Oka strain) 
as the Varicella vaccine, but at a much higher dose, proved its 
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efficacy in terms of reducing shingles and post-herpetic neuralgia 
incidences, of 51% and 67% respectively14. This vaccine received a 
marketing authorization in France for adults more than 60 years of 
age. 
VIROLOGY: 
Varicella – Zoster Virus 
VZV is a member of the herpesviridae family and shares 
structural characteristics with other members of the family. The 
virus has icosapentahedral symmetry and contains DNA with a 
surrounding envelope. The size of the virus is approximately 150 
to 200nm. 
The nucleo capsid has a diameter of approximately 90 to 95 
nm15, consisting of 162 hexagonal capsomeres with central axial 
hollow organised as an icosahedron with 5:3:2 axial symmetry16. 
A biological important coat, the tegument, surrounds the 
nucleocapsid, which in turn is surrounded by an envelope that is 
derived in part from cellular membranes.  The glycoproteins (gps) 
are termed I through VI. These glycoproteins have been the subject 
of intense investigative interest because they represent the primary 
markers for both humoral and cell mediated immune response.  
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VZV replicates in the nuclei of infected cells, where the DNA 
core and capsid are synthesized17. 
EPIDEMIOLOGY: 
Herpes zoster is a disease that occurs at all ages, but it afflicts 
about 20% or more of the population overall, mainly the elderly9.  
The highest incidence of disease varies between 5 and 10 cases per 
1000 for persons older than 60 years18.  
The incidence of zoster in children is low. Hope-Simpson29 
reported a rate of 0.74 per 1000 subjects per year in the age group 
9. Guess30 et al all noted that the rate increased from 20 cases per 
1,00,000 person - years in the age group younger than 5 years to 63 
cases per 1,00,000 person - years in the group aged 15 to 19 years.  
Immunocompromised persons have a higher incidence of 
both chickenpox and shingles19. Both sexes are equally affected. 
Geographic and racial factors have been reported in studies of the 
epidemiology of Varicella and herpes zoster. Non – Caucasian 
racial group and tropical region people were each significantly 
associated with younger age at Zoster onset in a study conducted by 
Nagasako et al21. It is a sporadic disease occurring throughout the 
year. Contagiousness of infection from zoster patient is low, as 
secondary attack rate within household non-immune contacts is 
about 15%22. 
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PATHOGENESIS: 
Primary viraemia of VZV: 
Airborne droplets are the usual route of transmission of 
primary Varicella (chickenpox). The incubation period ranges from 
11 to 20 days. Varicella is extremely contagious with 80 to 90% of 
susceptible household contacts developing clinical infection. 
VZV enters individual by infection of mucosal epithelial cells 
in the upper respiratory tract, oropharynx or conjunctiva. After 
primary replication in the epithelium, the virus is disseminated by 
the blood stream to the reticulo-endothelial system, where viral 
replication leads to secondary viremia.  Infection of capillary 
endothelial cells allows spread of the virus to epithelial cells of the 
epidermis, where focal cutaneous lesions of Varicella are formed. 
Host immunity limits the acute disease but during spread 
through the epidermal epithelium, the virus also infects sensory 
nerve endings and is transported to sensory ganglia. Latent 
infection is established in the ganglia, neurons and satellite cells23.  
LATENCY AND REACTIVATION: 
VZV evades the immune response to establish latency in an 
immunological privileged site and down regulates gene expression 
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there. It is believed that latent infection is established in a host cell 
that is non permissive for viral gene transcription. 
The configuration of VZV DNA in latently infected ganglia is 
extra chromosomal and circular24. Herpes zoster appears upon re-
activation of VZV which may occur spontaneously or may be 
induced by stress, fever, radiation therapy, surgery, tissue damage 
or immune suppression25. 
During herpes zoster reactivation, the virus continues to 
replicate in the dorsal root ganglion and produces a painful 
ganglionitis. Inflammation and neuronal necrosis can result in 
severe neuralgia that intensifies as the virus spreads down the sensory 
nerve. If the existing immune response cannot control the re-
activating virus, extensive viral replication can occur in the ganglia. 
Virus also spreads to the periphery by axonal transport 
through neurons innervating a specific dermatome or dermatomes. 
There the virus productively infects the epithelium to cause the 
lesion characteristic of shingles25. 
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HISTO - PATHOLOGY 
SKIN LESIONS: 
I. Early stage: 
The earliest changes involve the epidermal cell nuclei which 
develop peripheral clumping of chromatin and a homogenous 
ground glass appearance, combined with ballooning of nucleus26. 
Vacuolization is the earliest cytoplasmic alteration. These 
changes begin focally along the basal layer, but soon involve the 
entire epidermis26. 
II. Vesicular Stage:  
Intra epidermal vesicle results from two types of degenerative 
changes. 1). Ballooning degeneration & 2). Reticular degeneration.  
Ballooning degeneration is peculiar to viral vesicles. The 
affected cells swell and loose their attachment to adjacent cells, 
thus separating from them (secondary acantholysis)25. 
The cytoplasm of these cells becomes homogenous and 
intensively eosinophilic and some are multinucleate (Tzanck cells) 
11. At times the basal layer of the epidermis is also destroyed in this 
way, leading to the formation of a sub-epidermal vesicle. 
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Reticular degeneration25 is characterized by progressive 
hydropic swelling of epidermal cells, which become large and clear 
with only fine cytoplasmic strands remaining at the edge of the 
cells. These eventually rupture contributing further to the 
formation of a vesicle. 
Whereas ballooning degeneration is found mainly at the base 
of the vesicle, reticular degeneration is seen on its superficial 
aspect and margin. Multinucleated giant cells containing upto 15 
nuclei which are formed by fusion of epithelial cells containing 
eosinophilic intranuclear inclusion bodies (Lipschutz bodies, 
formerly Cowdry type A bodies)27 of 3 to 8 mm in diameter. 
III. Late stage:  
Eosinophilic intra nuclear inclusion bodies are found, 
particularly in ballooned cells. Neutrophils are present within 
established vesicles. Neutrophilic and lymphocytic infiltration is 
also present in the underlying dermis. Marked inflammation and 
vasculitis28 have been noted in some lesions. If the vasculitis is 
severe, necrotizing lesions will be present. Eccrine duct 
involvement has been reported. The chronic verrucous lesions show 
hyperkeratosis, verruciform acanthosis and virus-induced 
cytopathic changes29. 
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IMMUNOLOGY 
Both humoral and cell mediated immune responses to VZV 
develop within a few days after the onset of varicella. 
Peak antibody levels are attained after 4 to 8 weeks; remain 
high for about 6 months and then decline. IgG Ab to VZV can be 
detected in healthy adults for decades after varicella30. After active 
immunization against varicella antibody titers are lower than after 
natural infection but persists for as long as 20 years in healthy 
children. Serum IgG, IgA and IgM develop after both varicella and 
zoster. Zoster occurs in the face of high levels of specific antibodies, 
but significantly higher titers develop during convalescence, 
reflecting an anamnestic response to this reactivation infection31.  
Antibodies seem to have an incomplete protective effect. Cellular 
immunity is thought to play the major role in host defense against VZV.  
Natural killer cells and antibody dependent cellular cytotoxicity 
against VZV have also been described. It is generally agreed that 
CMI, presumable T cell cytotoxicity is more important than humoral 
immunity in recovery from infection32. 
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CLINICAL MANIFESTATIONS 
Pre - eruptive Stage: 
The first manifestation of zoster is usually pain, which may be 
severe and may be accompanied by fever, headache, malaise and 
tenderness localized to areas of one or more dorsal roots. 
The time between the start of the pain and the onset of 
eruption averages 1.4 days in trigeminal zoster and 3.2 days in 
thoracic disease33. The skin in the affected area becomes red and 
papules soon develop34. Occasionally the pain is not followed by the 
eruption (zoster sine eruptione, zoster signe herpete)35. 
In the pre eruptive stage the pain simulates headache, eye 
pain, dental pain, pleurisy, brachial neuritis, cardiac pain, intra 
abdominal disease (especially gall bladder colic, appendicitis, renal 
colic, etc.) or sciatic syndrome. Prodromal symptoms may be 
absent, particularly in children36. 
ERUPTIVE STAGE: 
Closely grouped red papules, rapidly becoming vesicular and 
then pustular develop in a continuous or interrupted band in the 
area of one, occasionally two and rarely more contiguous dermatomes. 
Mucous membranes within the affected dermatomes are also 
involved. The lymph nodes draining the affected area are enlarged 
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and tender. Occasionally a few vesicles appear across the midline36. 
Rarely eruption may be bilateral. 
Dermatome involvement in Herpes zoster: 
Thoracic - 53% (Commonest) 
Cervical - 20% 
Ophthalmic - 16% 
Lumbosacral - 11% 
Possibly because chicken pox is centripetal (located on the 
trunk), the thoracic region is affected in two thirds of herpes zoster 
cases36. 
RESOLUTION STAGE: 
The pain and constitutional symptoms subsides gradually as 
the eruption subsides, vesicles either umblicate or rupture before 
forming a crust, which falls off in 2 to 3 weeks. 
In uncomplicated cases the recovery is complete in 2 to 3 
weeks in children and young adults and 3 to 4 weeks in older 
patients33. 
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CEPHALIC ZOSTER: 
This includes involvement of cranial nerves, such as 
trigeminal nerve branches, facial nerve, auditory nerve, 
glossopharyngeal and vagal nerves. 
TRIGEMINAL NERVE ZOSTER 
It is due to involvement of Gasserian ganglion of the 
trigeminal nerve. Three branches of the trigeminal nerve such as 
ophthalmic, maxillary and mandibular divisions are affected by 
Herpes Zoster. 
HERPES ZOSTER OPHTHALMICUS: 
Herpes zoster ophthalmicus occurs when the recrudescence is 
in the ophthalmic branch of the trigeminal nerve. The ophthalmic 
involvement makes up to 10 to 15% of all cases of herpes zoster. V1 
area involves forehead and upper eyelid. Infection involving the 
cornea with keratitis and uveitis and may lead to permanent 
damage. This presentation occurs when the nasociliary branch of 
ophthalmic division is involved and accordingly presents with 
cutaneous involvement of the nasal tip (Hutchinson’s sign)37. 
Frontal sinusitis preceded 16% of all cases of ophthalmic 
zoster38. Patients with ophthalmic herpes zoster who are HIV 
negative tend to have less severe infection and also recover faster 
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than those who are HIV positive39.Herpes zoster ophthalmicus is a 
known marker of HIV/AIDS in Africa40. 
HERPES ZOSTER OF MAXILLARY DIVISION OF TRIGEMINAL 
NERVE: 
Zoster of maxillary division of the trigeminal nerve produces 
vesiculation of the tonsillar area, cheek, lower eyelid, side of the 
nose, upper lip as well as mucosa of nose, nasopharynx, palate, 
uvula and tonsillar area41. 
HERPES ZOSTER OF MANDIBULAR BRANCH OF TRIGEMINAL 
NERVE: 
The dermal and mucous membrane distribution of this 
branch is to the side of the head, part of the external ear and 
external ear canal, lower lip, anterior part of the tongue, floor of 
the mouth and buccal mucous membrane. In oro facial zoster 
toothache may be the presenting symptom. 
HERPES ZOSTER OTICUS/ RAMSAY-HUNT SYNDROME: 
The facial nerve, mainly a motor nerve, has vestigial sensory 
fibres supplying the external ear (including pinna and meatus), 
tonsillar fossa and adjacent soft palate. Classical sensory nerve 
zoster in these fibres causes pain and vesicles in part or all of that 
distribution, though the skin involvement may be minimal and 
limited to the external auditory meatus. 
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Swelling of infected sensory fibres in their course through the 
confined spaces of the facial canal and the internal auditory 
meatus, leading to compression of adjacent facial nerve motor 
fibres resulting in facial palsy, which with the ear pain and 
associated vesicle completes the classic triad of Ramsay-Hunt 
syndrome42. 
Auditory nerve involvement occurs in 37.2% of patients 
resulting in hearing deficits and vertigo43. 
GLOSSOPHARYNGEAL AND VAGAL ZOSTER (HERPES 
PHARYNGITIS AND HERPES LARYNGIS) 62: 
This type involves the jugular and petrosal ganglia. Because 
these two ganglia are adjacent, they are often involved in some 
combination together but may be affected separately. The vesicular 
rash is likely to be on the palate, back of the tongue, epiglottis or 
faucial tonsils and occasionally  in the external ear.  
Palatal weakness, dysphonia, difficulty in swallowing, 
hyperesthesia in pharynx, loss of gag reflex, etc may occur. There is 
usually ear or deep pharyngeal or laryngeal pain. 
HERPES OCCIPITOCOLLARIS (INVOLVEMENT OF C2 AND C3)44 
The skin lesions seen over the back of scalp, back of neck, 
part of the ear and part of the lower jaw and front of neck. C2 and 
C3 are often involved together. There are communicating branches 
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of C2 and C3 with VII and X cranial nerves. Combinations of C2 and 
C3 with these cranial nerves are possible.  
ZOSTER MENINGO ENCEPHALITIS: 
This manifestation is most likely to be marked when cranial 
nerves (especially Trigeminal Nerve) are involved. This is because 
of a branch (recurrent nerve of Arnold) to the tentorium from 
ophthalmic branch of Trigeminal Nerve. Hence meningeal reaction 
(i.e. headache, changes in sensorium , fever, stiffness of neck , etc) 
is  most common with herpes zoster ophthalmicus.  
SACRAL ZOSTER (S2, S3 AND S4 DERMATOMES): 
A neurogenic bladder with urinary hesitancy or urinary 
retention45 has reportedly been associated with zoster of the sacral 
dermatomes S2, S3 and S4. Migration of virus to the adjacent 
autonomic nerves is responsible for these symptoms. 
BILATERAL HERPES ZOSTER46 
Herpes zoster is almost always unilateral. The rarity of 
bilateral cases is indicated by individual case reports in the 
literature.  
HERPES ZOSTER WITH MULTIPLE UNILATERAL LESIONS47  
This type is quite rare and most likely to be noted in persons 
with some severe systemic illness i.e. Hodgkin’s lymphoma, 
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metastatic cancer, HIV, etc. Such diseases should be looked for 
when this dermal distribution is encountered. 
RECURRENT HERPES ZOSTER48 
Recurrent attacks are rare and zosteriform herpes simplex 
should always be ruled out49. 
ZOSTER IN MALIGNANCY: 
Herpes zoster has been reported with Hodgkin’s, lymphomas, 
leukemia, metastatic cancer and other neoplasm. The presence of 
Herpes zoster especially in an older person indicates the need for 
searching for these diseases as a causative background. Use of 
cytotoxic immunosuppressant therapy altering immune response 
may also be a factor. 
HERPES ZOSTER IN HIV INFECTION 
Herpes zoster is included in clinical stage - 2 of WHO staging 
system for HIV infection. 
Herpes zoster occurring in HIV disease is usually typical in 
involving one or two adjacent dermatomes but uncommonly it may 
be multidermatomal, recurrent within the same dermatome or 
disseminated50. The eruption may be bulbous, hemorrhagic, 
necrotic and may be accompanied by severe pain. 
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The majority of HIV infected patients with herpes zoster 
experience an uneventful recovery; however atypical clinical course 
of herpes zoster is not uncommon50. Lesions may persist for 
months, either in localized or disseminated form, appearing as 
hyperkeratotic, ulcerated, painful nodules, often with central 
crusting or ulceration with a border of vesicles51. Systemic 
dissemination of herpes zoster with hepatitis, encephalitis and 
pneumonitis is common. HIV infected patients with herpes zoster 
show increased neurologic and ophthalmic complications 
particularly peripheral retinal necrosis52. Reactivation of varicella 
zoster virus is the commonest cutaneous manifestation of immune 
restoration disease53. 
HERPES ZOSTER IN CHILDREN 
Herpes zoster in neonates and children may represent the 
result of an attenuated response to intra uterine or neonatal 
infection. Baba et al54 reported that children who had varicella 
before 2 months of age has lower varicella zoster antibody titers 
and diminished skin test reactions; thus reactivation in these cases 
may be secondary to an abnormal immune response to the primary 
infection by varicella.  
The development of herpes zoster is often preceded by 
radicular pain and is less common in children. Malaise, headache 
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and fever may precede the rash, particularly in younger patients. 
Resolution of  lesion occur within 1 to 3 weeks. 
Both normal and immunosuppressed patients may have 
generalization of herpes zoster. Post herpetic neuralgia is 
uncommon in children. Immunocompromised children with herpes 
zoster may have more extensive involvement with a higher risk of 
viremia and visceral dissemination.  
HERPES ZOSTER IN PREGNANCY: 
Herpes zoster during pregnancy, whether it occurs early or 
late in the pregnancy, appears to have no deleterious effects on 
either the mother or infant55. Maternal zoster in pregnancy is not 
associated with intra uterine infection56. But maternal Varicella in 
the first 20 weeks of pregnancy is associated with a approximate 
2% risk of fetal damage57.  
COMPLICATION 
1. Acute complications of herpes zoster: 
Acute complications occur during the course of illness and  
are more common in immunocompromied individuals. 
i. Cutaneous Complications 
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The common cutaneous complications are secondary  bacterial 
infections, cutaneous necrosis, scarring, dissemination and gangrene 
formation.  
ii. Ocular Complications58  
Ocular complications include uveitis, keratitis,  
conjunctivitis, conjunctival edema, ocular muscle palsies, 
proptosis, scleretis, retinal vascular occlusion and ulceration, 
scarring and even necrosis of the lid. Involvement of ciliary ganglion 
may give rise to Argyl-Robertson pupil.  
Acute retinal necrosis caused by Varicella-zoster virus 
occasionally occurs in immuno-competent patients, although more 
recent studies have focused on ocular disease in HIV infected patients59. 
iii. Neurological Complications: 
This includes cranial neuritis, motor neuropathy autonomic  
neuropathy, aseptic meningitis, meningo-encephalitis, 
transverse myelitis60, necrotizing myelopathy, Guillain-Barre 
Syndrome, hemiplegia and granulomatous angiitis. 
a) Cranial Neuritis: 
Cranial neuritis includes trigeminal nerve zoster (Herpes 
zoster opthalmicus, maxillary and mandibular nerve zoster), 
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Ramsay-Hunt syndrome with involvement of facial nerve and 8th 
cranial nerve, vagus and glossopharyngeal nerve zoster.  
 
b) Motor Neuropathy: 
This occurs overall in 5% of cases and is more common in 
older patients and those with malignancy and in cranial when 
compared with spinal nerve involvement. The motor weakness 
usually follows the pain and the eruption by a few days to a few 
weeks, but occasionally precedes or accompanies them. The 
affected segment is usually but not always the same. Complete 
recovery is expected in 55% and significant improvement in a 
further 30% of cases. In ophthalmic zoster, ocular palsies occur in 
13% and facial palsies in 7%61. An abdominal hernia followed zoster 
involving thoracic 10th and 11th motor roots62. zoster of ano-genital 
area may be associated with disturbances of defecation or 
urination63. Herpes zoster oticus accounts for about 10% of cases 
facial palsy64. Glossopharyngeal65 and vagal zoster66 produces 
pharyngeal and palatal muscle weakness. Zoster of the second to 
fourth cervical nerves may paralyze the ipsilateral diaphragm due 
to involvement of the phrenic nerve. 
c) Autonomic Neuropathy: 
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Autonomic nervous system may also be affected. Autonomic 
nerve involvement often presents as bladder dysfunction. Gastro-
intestinal tract involvement presents as spasm, hypotonia or ileus. 
d) Herpes zoster Meningo - encephalis 
Neurologic symptoms characteristically appear within the 
first 2 weeks of onset of the skin lesions. Patients at risk are those 
with trigeminal and disseminated zoster as well as the 
immunosuppressed. Rarely manifestations of a meningo-
encephalitis may be significant and at times severe enough to cause 
death. 
e) Granulomatous angiitis67 (or) Delayed contra-lateral 
hemiparesis: 
By direct extension along the intracranial branches of the 
trigeminal nerve, VZV gains access to the CNS and infects the 
cerebral arteries. Patients present with headache and hemiplegia.  
f) Herpes zoster Myelitis: 
More rarely, the myelitis lesion predominates in zoster or is 
the sole feature, so the clinical picture is one of acute onset of 
paraplegia from a diffuse involvement of the spinal cord. The 
picture is that associated with acute transverse myelopathy. 
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iv. Visceral Complications: 
Patients with lympho-proliferative malignancies are at risk 
for cutaneous dissemination and visceral involvement, including 
Varicella pneumonitis, hepatitis and meningo-encephalitis. 
2. Complications occurring after resolution of Herpes  
Zoster lesions: 
i. Post Herpetic Neuralgia 
The commonest and most intractable sequel of zoster is Post-
herpetic neuralgia, generally defined as persistence or recurrence of 
pain for more than a month after the onset of zoster, but better 
considered after 3 months. It occurs in about 30% of patients over 
40 years of age and is most frequent when trigeminal nerve is 
involved68. 
The pain has two main forms, a continuous burning pain with 
hyperaesthesia and spasmodic shooting type, although a pruritic 
“crawling” paraesthesia may occur. Allodynia, pain caused by 
normally innocuous stimuli, is often the most distressing symptom 
and occurs in 90% of people with post herpetic neuralgia68.  
Patho-physiology of pain 
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A number of different overlapping mechanisms appear to be 
involved in the pathogenesis of pain in herpes zoster and post 
herpetic neuralgia68. 
Injury to the peripheral nerves and to neurons in the ganglion 
triggers afferent pain signals. Inflammation in the skin triggers 
nociceptive signals that further amplify cutaneous pain. The 
abundant release of excitatory aminoacids and neuro-peptides 
induced by the sustained barrage of afferent impulses during the 
prodrome and acute phase of herpes zoster may cause excito-toxic 
injury and the loss of inhibitory inter-neurons in the spinal dorsal 
horn. 
ii. Post Herpetic Itch69: 
Many patients with shingles experience neuropathic itch 
accompanying pain or itch may be present instead of pain.  
iii. Progressive multifocal leuko-encephalopathy 
In addition to latent infection, VZV can produce prolonged 
smouldering sub-clinical infection in patients lacking normal 
defenses to eliminate the viral infected cells and resulting in cell to 
cell spread of infection. 
iv. Scarring: 
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Elderly, malnourished, debilitated or immuno-suppressed 
patients tent to have a more virulent and extensive course of 
disease and Scarring. Sometimes keloidal or hypertrophic scars 
follows  herpes zoster. 
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v. Inflammatory skin lesions following a zoster infection 
(Isotopic Response) 
Following zoster, inflammatory skin lesions may rarely occur 
within the affected dermatome. Lesions usually appear within a 
month and rarely, longer than 3 months after zoster.  
Lesions reported in herpes zoster scar include a keloid, 
comedones, lichen planus, giant cell lichenoid dermatitis, urticaria, 
granulomatous vasculitis, granulomatous folliculitis, sarcoidosis, 
lichen sclerosis et atrophicus, morphoea, eosinophilic dermatosis, 
fungal infections, pseudolymphoma, lymphoma, leukemia cutis, 
Rosai-Dorfman disease, Kaposi’s sarcoma, various skin cancers and 
metastasis70.  
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DIAGNOSIS OF HERPES ZOSTER 
CLINICAL DIAGNOSIS 
The diagnosis is largely clinical. Grouped vesicles of varying 
sizes on an oedematous and erythematous base with skipped areas 
of normal skin in a dermatomal distribution makes the diagnosis of 
herpes zoster, quiet obvious most of the times. 
INVESTIGATIONS: 
1. Morphological test 
Tzanck Smear: 
The initial test of choice is a cytological smear (Tzanck 
smear). The test does not differentiate herpes simplex from 
varicella. The base of an early lesion is scraped and stained with 
haematoxylin and eosin, Giemsa, Wright’s stain, toluidine blue or 
papanicolaou stain. Multinucleated giant epithelial cells and 
epithelial cells containing acidophilic intranuclear inclusions are 
seen.  
2. Skin Biopsy:  
Histo-pathological appearances of herpes simplex, varicella 
and herpes zoster are very similar. Ballooning degeneration is 
peculiar to viral vesicles. Whereas ballooning degeneration is found 
 
30
mainly at the base of the vesicle, reticular degeneration is seen on 
its superficial aspect and margin. 
3. Virological Investigations:  
a) Viral Culture: 
The most definitive test is a positive viral culture from 
vesicular fluid, but a minimum of 48 to 72 hours is required to 
produce the diagnostic cytopathic effects. Infective material is 
inoculated into human amnion, human fibroblast, HeLa71 or Vero 
cells. 
b) Varicella zoster virus antigen detection: 
VZV antigen may be demonstrated by immunoflourescence, 
using a commercially available monoclonal antibody to VZV that is 
conjugated to flourescin72. 
c) Electron Microscopy: 
The ultra-structural features of Varicella zoster virus are 
similar to those of Herpes simplex virus. However colloidal gold  
immuno-electron microscopy using monoclonal antibodies can 
distinguish between the two conditions73. 
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4. Serological Tests: 
A number of sensitive serologic tests are available to measure 
antibodies to VZV) 
Serologic tests include 
1. Fluorescent antibody to membrane antigens (FAMA) 
2. Latex agglutination test 
3. Enzyme linked immunosorbent assay (ELISA) 
4. Enzyme Immuno assay (EIA) 
5. Immune adherence haemagglutination assay (IAHA) 
6. Radio Immuno assay (RIA) 
7. Complement fixation test (CFT) 
8. Varicella zoster virus neutralization tests. 
5. Newer Techniques: 
i. Nucleic acid probes 
The nucleic acid hybridization test has also been described 
for the detection of Varicella zoster virus DNA sequences in clinical 
specimens. The spot hybridization assay used was comparable to 
cell culture in sensitivity and specificity. 
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ii. Polymerase Chain Reaction: 
PCR is more sensitive than viral culture or Tzanck smear for 
detecting VZV infections. PCR was described as particularly useful 
for the rapid and specific diagnosis of VZV infections without the 
practical and technical limitations of conventional viral isolations 
or Tzanck smears74. 
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TREATMENT 
The aim of treatment is the suppression of inflammation, 
pain and infection. 
TOPICAL TREATMENT: 
During acute phase of herpes zoster, the application of wet 
compresses, calamine lotion, Burrow’s solution cornstarch, or 
baking soda may help to alleviate local symptoms and hasten the 
drying of vesicular lesions.75  
Topical Acyclovir 
Topical treatment of herpes zoster rash with antiviral agents 
is not effective75 
Systemic Therapy 
The major goals of therapy in patients with herpes zoster are 
to limit the extent, duration and severity of pain and rash in the 
primary dermatome and to prevent disease elsewhere and PHN.  
SYSTEMIC ANTIVIRAL AGENTS 
1. ACYCLOVIR 
Oral acyclovir significantly reduced the healing time, 
duration of viral shedding and acute pain in randomized controlled 
trials in patients older than 50 years of age who were treated within 
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72 hours of rash onset76. Aciclovir is a guanosine analogue and is 
widely used for the treatment of HSV and VZV infections.  
MECHANISM OF ACTION: 
The active antiviral moiety aciclovir is aciclovir triphosphate, 
which is a potent inhibitor of certain herpesvirus induced DNA 
polymerases, but has relatively little effect on host cell DNA 
polymerase.  
INDICATIONS AND DOSAGE: 
Varicella zoster virus is less sensitive to aciclovir than HSV, 
higher doses of the drug should be used. 
ORAL: 
Indications: 
1. Immunocompetent persons with age 50 years or 
above25. 
2. Immunocompetent patients with ophthalmic zoster. 
3. Localised zoster (one or two dermatome) in asymptomatic 
HIV positive patients77. 
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Dosage: 
800 mg 5 times a day (in adults) or 20 mg/kg every 6 hours 
(in children) for 7 days in immunocompetent individuals and 10 
days for immunocompromised.  
INTRAVENOUS ACICLOVIR: 
1. Disseminated or localized zoster involving more than 3 
dermatomes in immunocomprised patients. 
2. Chronic, severe zoster in advanced AIDS patients77. 
3. Zoster involving cranial nerves with complications such 
as Ramsay - Hunt Syndrome25 or Ophthalmic zoster in 
HIV patients77. 
4. Visceral dissemination25. 
5. Localised zoster in HIV positive patients with impaired 
intestinal function (i.e. diarrhea or malabsorption) 
where intravenous route is preferred to ensure adequate 
drug level. 
6. Herpes Zoster encephalitis 
Dose: 500mg/m2 in children or 10mg/kg body weight in 
adults, infused over one hour at every 8 hours for 7 to 10 days. 
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2. VALACYCLOVIR: 
It is the L-valine ester of aciclovir. It was developed to provide 
increased oral bioavailability of aciclovir78. Valacyclovir may be more 
effective in resolution of zoster associated pain79. Dose: 1 gm tds for 7 days. 
3. FAMCICLOVIR AND PENCICLOVIR: 
Famciclovir is a prodrug of pencilovir. Penciclovir is 
phosphorylated to penciclovir triphosphate. Penciclovir 
triphosphate inhibits viral DNA polymerases and also inhibits 
extension of the nascent viral DNA chain80. Dose: Farmciclovir 
500mg tid for 7 days. 
4. FOSCARNET (TRISODIUM PHOSPHONOFORMATE) 
It is a pyrophosphate containing compound that is active in 
vitro against varicellar zoster virus. Forcarnet noncompetitively 
inhibits viral DNA polymerases at the pyrophosphate binding81 
sites.  
Dosage: 
Initial dosage of 40 to 60mg / kg administered intravenously, 8th 
hourly for 14 to 21 days followed by a maintenance dose of 
120mg/kg/day. 
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5. CIDOFOVIR: 
It is a phosphonate nucleotide analogue. It has activity 
against a broad range of herperviruses. 
Cidofovir does not require initial phosphorylation by virus 
induced kinases, but is converted by host cell enzymes to cidofovir 
diphosphate which is a competitive inhibitor of viral DNA 
polymerases and to a lesser extent of host cell DNA polymerases. 
6. VIDARABINE (ADENINE ARABINOSIDE) 
It is an adenosine analogue which is phrosphorylated 
intracellularly by host enzymes and rapidly metabolised to 
hypoxanthine arabinoside by adenosine deaminase, resulting in 
markedly reduced antiviral activity within the cells. This instability 
and systemic toxicity have limited its use82. Dose: 10mg/kg/day 
infused over 12 hours for 5 days.  
7. IDOXURUDINE 
This synthetic nucleoside is effective against DNA viruses, 
particularly the herpes group. Its use is now restricted to topical 
application because of severe bone marrow and hepatic toxicity 
when given intravenously.  
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RECENT DRUGS: 
(1)  Sorivudine: 
It is an uracil analogue with activity against VZV infections. It 
requires viral thymidine kinase for phosphorylation.  
(2)  Brivudine: 
It is a new uracil derivative with potent and specific activity 
against VZV. It is effective in a single or twice daily dose orally  
(50 to 200 mg) in immunocompetent adults and older patients 83. 
In immunocompromised patients, it is as effective as iv aciclovir in 
the dose of 125mg tablet every 6 hours.  
(3)  Oral enzyme therapy: 
Oral enzyme therapy is beneficial in diseases characterized in 
part by TGF-β over production that included slingles patients84.  
(4)  Human Interferon-A 
Interferons are synthesized by DNA recombinant technology. 
Is nonspecific antiviral effects, involving synthesis of RNA and 
additive protein, with immunomodulatory effects, help in preveting 
VZV synthesis and elimination of infected cells. 
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ROLE OF STEROIDS IN HERPES ZOSTER MANAGEMENT: 
Combination  therapy of steroid and aciclovir resulted in an 
improved quality of life, as measured by reductions in the  use of 
analgesics, the time to uninterrupted sleep, and the time to resumption 
of usual activities85. However, neither study demonstrated any effect of 
corticosteroids on the incidence or duration of post herpetic neuralgia.  
Treatment of acute pain associated with herper zoster: 
For acute pain scheduled short acting narcotic analgesics 
should be prescribed. For persistent pain, long acting, controlled -
release opioids are preferred. If pain control remains inadequate 
then regional or local anesthetic nerve blocks should be considered. 
The effectiveness of carefully managed opiates, and tricyclic 
antidepressants during the acute phase of herpes zoster in reducing 
the incidence, duration of severity of PHN is not known. 
Intradermal  steroids, xylocaine and epinephrine can also be given. 
TREATMENT OF POST HERPETIC NEURALGIA:  
TOPICAL THERAPY: 
1. Topical lidocaine patch86 
2. Topical EMLA cream 
3. Topical Capsaicin (0.025%)cream 
4.  Topical aspirin tablets in chloroform33 
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5.  Doxepin cream (5%)88 
SYSTEMIC TREATMENT 
1)  Anticonvulsants 
For stabbing pain, sodium valproate, clonazepam, 
carbamazepine and Gabapentin are effective. 
2) Tricyclic antidepressants: 
Desipramine. nortriptyline, maprotiline, Amitriptyline, are 
effective in post herpetic neuralgia. They are thought to act 
independent of their antidepressant actions.  
(3)  Oxycodone: 
controlled release oxycodone (10mg every 12 hours) is an 
effective analgesic for the management of steady pain, paroxysmal 
spontaneous pain and allodynia.  
(4)  Analgesics: 
Aspirin and other non steroidal anti inflammatory drugs 
are commonly used in  patients with post herpetic neuralgia, but 
their value is limited. Tramodol87, a centrally acting analgesic 
with opioid and non opioid activities also effective in post 
herpetic neuralgia (maximum dose 600mg / day) 
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(5)  Anti psychotics 
Fluphenazine, chlorprothixene, and perphenazines are used 
with other drugs. 
OTHER MODALITIES OF TREATMENT: 
1. Intrathecal methyl Prednisolone 
2. Intradermal steroids, xylocaine and epinephrine 
injection. 
3. Sympathetic blocks (stellate ganglion or epidural) with 
0.25% bupivacaine prevents or relieves post herpetic 
neuralgia. Epidural injection are made at or just above 
the highest dermatome of the rash. 
4. TENS (Transcutaneous electrical nerve stimulation) 
may be helpful.  
5. Acupuncture25 
6. Spinalcord stimulators. 
7. Bio feed back25 
8. Jaipur block89  
This consists of local subcutaneous infiltration of 2% 
lignocaine, 0.5% bupivacaine, and 4mg /ml 
dexamethasone, 2.5 ml each taken in a syringe and from 
which 4 to 5 ml of clear solution is given blindly at 
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about 4 to 10 sites in one sitting. By this method, 
reported from India, 28% reported complete relief at 6 
weeks, 57% after second injection and 11% after third 
injection89. 
SURGICAL PROCEDURES 
1. Division of dorsal root / tracotomy. 
2. Rhizotomy (surgical separation of pain fibres) 
3. Electrocoagulation of well defined area of dorsal root89. 
4. Electrical stimulation of thalamus and spinal cord. 
5. Anterolateral cordotomy89. 
PREVENTION OF HERPES ZOSTER 
(Zoster vaccine live (oka /merck)90 
A subcutaneously administered live high titre (18,700 to 
60,000 plaque -forming units per dose) varicella-zoster virus 
vaccine (zoster vaccine) of the oka/ Merck strain has been 
evaluated for the prevention of hesper zoster and the reduction of 
zoster associated pain in adults aged 60 years or above. 
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AIMS OF THE STUDY 
The study of herpes zoster was undertaken to findout: 
1. Age incidence 
2. Sex Incidence 
3. Prevalence of prodromal symptoms 
4. Predominant complaints given by patients. 
5. Prevalence of constitutional symptoms. 
6. Pattern of dermatomal involvement. 
7. Prevalence of association with HIV. 
8. Association with cutaneous disease, if any. 
9. Association with systemic disease, if any. 
10. Duration of time taken for resolution of lesions. 
11. Prevalence of complications. 
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MATERIALS AND METHODS 
The study was conducted between July 2005 and July 2007 at 
the department of Dermatology, Madras Medical College, Chennai, 
on hundred cases of herpes zoster. All cases of herpes zoster 
attending skin out patient department and referred cases of zoster 
from other departments were studied. 
Patient’s age, sex, occupation, and address were noted. A 
detailed history regarding the prodromal symptoms, skin lesions, 
nature of pain, duration of illness at the time of presentation, 
provocative factors were recorded. Associated cutaneous disease, 
systemic disease and HIV infection were recorded. History of 
chicken pox and previous attack of zoster were elicited and time 
taken for complete resolution of lesions were noted. Complications 
of herpes zoster and association with HIV were also recorded. 
Each patient underwent detailed general physical and 
systemic examinations. A thorough dermatological examination 
was done in all cases and the following details were noted. 
1. Site of lesion (segment involvement) 
2. Morphology of lesions like grouped vesicles, scattered 
vesicles, erythema, papules, erosions and crusting. 
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3. Dermatomal distribution & the side of involvement.  
4. Cutaneous dissemination. 
5. Lymph node enlargement. 
6. Mucosal lesions. 
7. Motor zoster 
8. Other cutaneous diseases. 
The diagnosis of herpes zoster was made clinically on the 
basis of characteristic presentation of vesicles in dermatomal or 
disseminated pattern. Diagnosis was confirmed with Tzanck smear 
and skin biopsy whenever required. A set of laboratory 
investigation consisting of complete hemogram, blood sugar, renal 
function test, urine analysis, ELISA for HIV antibody were done in 
all cases. Whenever necessary, other specialist’s opinions like 
ophthalmologist, physician, neurologist and diabetologist were 
sought. 
All patients were treated with oral aciclovir. Systemic 
antibiotics were given for cases with secondary bacterial infection 
and erosions. Patients with intractable zoster pain were given 
carbamazepine or amitriptyline and analgesics. In addition to 
systemic therapy, topical soothening agent like zinc oxide - 
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calamine lotion, or topical antibiotic creams were given. These 
patients were assessed with regards to the course of the disease, 
resolution time, pain relief and complications. 
All the patients were reviewed every 4 days, until the time of 
complete healing. After that patients were followed once weekly or 
more frequently depending upon the cases and complications 
encountered till the resolution of problems. 
During the follow up period the following complications were 
noted. 
1. Secondary bacterial infection. 
2. Dissemination 
3. Ulceration 
4. Delayed healing 
5. Post inflammatory hypo or hyperpigmentation. 
6. Scarring 
7. Post herpetic neuralgia. 
8. Other complications, if any. 
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OBSERVATIONS 
AGE AND SEXWISE PREVALENCE OF ZOSTER 
Table - I 
S.No Age Group Male Female Total no. of cases Percentage 
1. 1-10 Nil 1 1 1% 
2. 11-20 6 3 9 9% 
3. 21-30 17 8 25 25% 
4. 31-40 12 2 14 14% 
5. 41-50 18 6 24 24% 
6. 51-60 6 5 11 11% 
7. 61-70 11 3 14 14% 
8. 71-80 1 - 1 1% 
9. 81-90 1 - 1 1% 
 Total 72 20 100  
Out of 100 cases 72 were males and 28 were females. 
Age wise distribution (Table-1) shows that 73 cases were 
below the age of 50 and 27 were above the age of 50 years. 
Maximum number of cases were seen between the age group 
of 21 to 30 years (25%) and 41 to 50 years (24%) which was 
followed by 31 to 40 years (14%) and 61 to 70 years (14%). 
Minimum number of cases were observed in the age group of 1 to 10 
years (1%), 71 to 80 years (1%) and 81 to 90 years (1%). 
The youngest was 9 years and oldest was 81 years of age. 
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Out of 100 cases, 72 were males and 28 were females and the 
sex ratio is 2.5: 1 (male: female) approximately. 
2. PREVALENCE OF PRODROMAL SYMPTOMS 
The following prodromal symptoms were recorded. 
1. Fever and pain 
2. Dermatomal pain 
3. Burning sensation 
4. Itching 
5. Tingling, numbness, paraesthesia 
6. Ear pain  
7. Tooth ache 
8. Erythema 
Prodromal symptoms were present in 85 cases and absent in 
15 cases. Dermatomal pain prior to the onset of lesions was the 
commonest prodromal symptom (57%). The next common 
prodromal symptom seen was burning sensation (10%). Fever and 
pain was present in 6% of cases. Itching was present in 4% of cases. 
Ear pain and tooth ache were present in one case of herpes zoster 
oticus and one case of mandibular nerve zoster respectively. 
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Table -2 : Prevalence of prodromal symptoms 
S.No Prodromal Symptom Total no. of cases Percentage 
1.  Dermatomal pain 57 57% 
2.  Fever and pain 6 6% 
3.  Burning Sensation 10 10% 
4.  Itching 4 4% 
5.  Tingling, numbness, 
paraesthesia 
4 4% 
6.  Ear Pain 1 1% 
7.  Tooth Ache 1 1% 
8.  Erythema 2 2% 
9.  Absence of prodromal 
symptoms 
15 15% 
3. DURATION OF ILLNESS AT THE TIME OF PRESENTATION 
TO THE HOSPITAL: 
Out of 100 cases, 74% of cases presented with vesicular 
lesions within 5 days of onset of lesions. The remaining 26% of 
cases were presented after 6 days and above to the hospital. The 
complications like secondary infection and PHN were maximum in 
those cases came for treatment late in the course of the disease. 
Table - 3: Duration of illness at the time of presentation 
S.No Duration of illness Total no. of cases Percentage 
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1.  2 days 18 18% 
2.  3 days 20 20% 
3.  4 days 26 26% 
4.  5 days 10 10% 
5.  6 days 4 4% 
6.  7 days 12 12% 
7.  8 days & above 10 10% 
  100  
4.  PREVALENCE OF PRESENTING COMPLAINTS AND 
CONSTITUTIONAL SYMPTOMS 
Most common presenting complaint was pain in 99% of cases. 
In 57% of cases  pain was present prior to the onset of lesions and 
the remaining 42% of cases developed pain during evolution of 
vesicles. 
Vesicular lesion was the next common presenting complaint 
in 98% of cases and it was present in association with pain in 
almost all cases. 
Other presenting complaints were erosions, crusting, itching 
and burning sensation in very few cases (1 to 2 %). Headache and 
watering in the eye were present in 6 % of cases of ophthalmic 
zoster. Facial palsy was the presenting complaint in 1% of case. 
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Fever was the most common constitutional symptoms present 
in 45% of cases other constitutional symptoms present with fever 
were myalgia (18%), headache (12%) and joint pain (2%).  
5. MORPHOLOGY OF LESION AND PATTERN DERMATOME 
INVOLVEMENT: 
Grouped vesicles with erythematous background in 
dermatomal distribution were present in 97% of cases. The 
remaining 3% of cases had crusting and erosion alone. Other 
lesions presented with grouped vesicles were pustules, erosions and 
crusting. Oral erosions were seen in 2% of cases of maxillary and 
mandibular nerve zoster. 
Redness of eyes and eyelid edema were present in 6% of cases 
of ophthalmic zoster.  
Thoracic dermatome was the most common dermatome 
involved (60%) followed by cervical in 9% of cases, ophthalmic 
zoster in 8% of cases and lumber segment in 7% of cases. 
The prevalence of maxillary, mandibular and herpes zoster 
oticus was 2% each. 
Thoracolumbar and cervicothroracic involvement was 6% and 
3% respectively. The least common dermatome involved was sacral 
dermatome (1%) 
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The pattern of dermatome involvement was almost similar in 
both sexes. 
Dermatome involvement was predominantly on the left side 
(52%) when compared to right side (48%). But in lumbar, cervical 
and opthalmic zoster right side was commonly involved. 
Table-4 : Pattern of dermatome involvement: 
Sex Side 
S.No Dermatome 
Male Female Left Right 
No. 
of 
cases 
Percentage 
1. Thoracic 47 13 36 24 60 60% 
2. Lumbar 4 3 1 6 7 7% 
3. Cervical 5 4 2 7 9 9% 
4. Sacral 0 1 1 0 1 1% 
5. Thoraco Lumbar 5 1 3 3 6 6% 
6. Cervico thoracic 1 2 1 2 3 3% 
7. Ophthalmic  7 1 3 5 8 8% 
8. Maxillary 1 1 1 1 2 2% 
9. Mandibular 1 1 2 0 2 2% 
10. Herpes zoster 
oticus 
1 1 2 0 2 2% 
 TOTAL CASES 72 28 52 48 100  
6. MULTIDERMATOMAL INVOLVEMENT AND DISSEMINATION 
Multidermatomal involvement was noted in a case of herpes 
zoster oticus. The affected patient was an elderly man (70 years) 
with carcinoma prostate. He had involvement of C2, C3 and C4 
segment in addition to herpes zoster oticus with facial  palsy on the 
left side. 
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Cutaneous dissemination was noted in 2 cases in addition to 
the classical dermatomal distribution of grouped vesicles. One 
patient was a 36 year old male with HIV infection and another 
patient was a 65 year old male with no underlying 
immunosuppression or malignancy. 
No recurrence of herpes zoster was observed in any case. 
7. LYMPH NODE ENLARGEMENT: 
Regional lymph node enlargement was noted in 95% of cases. 
Nodes were tender in 80% of cases and non tender in 15% of cases 
and are firm in consistency. Generalised lymphadenopathy (PGL) 
was present in twelve HIV positive cases. 
8. PROVOCATIVE FACTORS: 
Out of 100 cases, 36 cases were having one or more suspected 
provocative factors. Among the 36 cases, 16 cases (44.4%) were 
having HIV, 7 cases (19.4%) were having diabetes and 5 cases 
(13.8%) were on steroid therapy for SLE (3 cases) and bronchial 
asthma (2 cases). 
Table - 5 
PREVALENCE of provocative factors 
S.No. Provocatve Factors Male Female Total % 
1.  HIV 14 2 16 44% 
2.  Physical Stress (Parturition) 0 1 1 2.7% 
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3.  Diabetes 6 1 7 19.4% 
4.  Renal transplantation  1 0 1 2.7% 
5.  Steroid therapy 2 3 5 13.8% 
6.  Hansen’s disease 1 0 1 2.7% 
7.  Pulmonary Tuberculosis 1 0 1 2.7% 
8.  Pregnancy 0 1 1 2.7% 
9.  Radiotherapy 0 2 2 5.5% 
10.  Malignancy  
(Prostate cancer) 
1 0 1 2.7% 
 TOTAL 26 10 36  
Hansen’s disease and tuberculosis were also present in 2 
cases of herpes zoster. Physical stress of parturition was suspected 
as a provocative factor of zoster in a case of postpartum female. 
Immunosuppression of pregnancy was the probable cause for zoster 
in an antenatal case (2.7%). 
A renal transplant patient (2.7%) on azathioprine therapy 
developed herpes zoster. Two female patients on radiotherapy for 
carcinoma breast and carcinoma cervix had herpes zoster (5.5%). 
One male patient (2.7%) with carcinoma prostate developed 
multidermatomal herpes zoster with herpes zoster oticus. 
Among the 16 HIV positive cases 14 were males and 2 were 
females. 
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9. PAST HISTORY OF CHICKEN POX: 
Table-6 : Age group - wise past history of Chicken Pox 
S.No. Age Group Male Female Total % 
1.  1-10 years of age 23 8 31 31% 
2.  11-20 years of age 22 10 32 32% 
3.  H/o. chicken pox in 
childhood (exact age not 
known) 
18 9 27 27% 
4.  No history of chicken pox 9 1 10 10% 
 Total 72 28 100  
Out of 100 cases, 90% gave definite history of occurrence of 
chicken pox out of 90 cases. 27% of patient did not give the exact 
age of occurrence of chicken pox. 32% of cases gave history of 
chicken pox between 11 to 20 years of age and 31% of cases gave 
history of vericella between 1 to 10 years. The remaining 10% of 
cases were either not aware of or not had chicken pox at all. 
10. ASSOCIATED  CUTANEOUS AND SYSTEMIC DISEASES: 
Cutaneous diseases seen in association with herpes zoster 
were acne 1 case, seborrhoeic dermatitis two cases, tinea versicolor 
2 cases, SLE 3 cases, Hansen‘s disease 1 case, insect bite allergy 2 
cases, wart 1 case, cellulitis 1 case, oral candidiasis 1 case, tinea 
cruris 1 case and intertrigo 1 case. Most of these cases were seen in 
association with immunosuppression. 
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Diabetes (7 cases) was the most common systemic disease 
seen in association with herpes zoster. The next common systemic 
disease seen with zoster was hpertension (6 cases). Other systemic 
diseases seen with herpes zoster were SLE (3 cases), bronchial 
asthma (2 cases), tuberculosis (1 case), Hepatitis B (1 case) and 
chronic renal failure (1 case). 
11. TIME TAKEN FOR RESOLUTION OF LESIONS: 
Most cases (50%) showed complete resolution of lesions 
between 15 to 21 days (3rd week). All patients were given T. aciclovir 
800mg 5 times a day for 8 days except for immunocompromised 
patients and they were given aciclovir for 10 days. The response to 
aciclovir was good and resolution was rapid unless there was 
secondary bacterial infection or underlying immunosuppression. 
Table - 7 :  Resolution time of zoster lesions 
S.No. Duration No. of cases % 
1.  8 to 14 days 35 35% 
2.  15 to 21 days 50 50% 
3.  22 to 28 days 14 14% 
4.  29 days and above 1 1% 
Resolution of lesions occurred within 8 to 14 days (2 weeks) 
in 35% of cases and in the range of 22 to 28 (wihtin 3 weeks) days 
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in 14% of cases. One case with underlying immunosuppression and 
necrotic lesion resolved at 29 days. 
12. INVESTIGATIONS: 
Complete hemogram was within normal limits except for 
increasecd eosinophil count in 6 patients, increased ESR in 20 
patients, increased neutrophil count in 6 patients, decreased 
haemoglobin value in 4 patients. 
Blood sugar was elevated above the normal valve in 7 
patients. Urine routine examination was normal in almost all 
patients (98%). Urine examination showed reducing sugar in 2 
patients with elevated blood glucose value. 
ELISA test for HIV antibody was done in all patients. Positive 
ELISA test result was obtained in 6 cases. 10 patients were already 
diagnosed as HIV Positive and presented with zoster during the course 
of HIV disease 
ECG was taken for patients with zoster involving left thoracic  
segment and it was found to be normal. 
One patient with SLE had elevated blood urea and serum 
creatinine  values and nephrologist opinion obtained for her and 
she was diagnosed as a case of SLE nephropathy. 
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Diabetologist opinion for 3 patients, neurologist opinion for 
13 patients, ophthalmologist opinion for 8 patients and ENT 
surgeon opinion for one case of herpes zoster oticus were obtained. 
Tzanck smear was positive in 95% of cases and negative in 5% of 
cases who presented late and those with ulcerations, erosions and 
crusting. 
Skin biopsy was done in 2 patients with erythematous 
plaques studded with very few grouped papules in a dermatomal 
pattern, in the pre eruptive stage, which under light microscope in 
haematoxylin and eosin staining showed intraepidermal 
uniloculated to multiloculated bullae with ballooned epithelial cells 
and multinucleated giant cells. Reticular degeneration seen in some 
areas. The upper dermis showed inflammatory infiltration. 
13. COMPLICATIONS: 
a.  Secondary bacterial infection: 
Secondary bacterial infection was reported in 15 cases 
(37.5%). In 2% of patients with secondary infection scarring 
occurred in affected dermatome. Cases were treated with topical silver 
sulphadiazine cream and systemic antibiotics in addition to aciclovir. 
b.  Scarring: 
 
59
Scarring was noted in 5 cases (12.5%) out of 5 cases, 3 cases 
had erosions and ulcerations of the lesion and 2 cases were 
associated with secondary bacterial infection and later developed 
ulceration. 
c.  Motor Zoster: 
Facial palsy was seen in a patient (2.5%) with Ramsay Hunt 
Syndrome with underlying prostatic carcinoma. 
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Table - 8  
PREVALENCE  OF COMPLICATIONS  
Complication M F T Percentage 
Scarring 5 0 5 12.5% 
Secondary bacterial infection 12 3 15 37.5% 
Post herpetic neuralgia 14 5 19 47.5% 
Motor Zoster 1 0 1 2.5% 
TOTAL 32 8 40  
d) Post herpetic neuralgia: 
PHN is the most feared complication in immunocompetent 
patients. Both the incidence and duration of post herpetic neuralgia 
are directly correlated with the patient’s age. Out of 40 patients  
with complications of zoster, 19 cases (47.5%) developed post 
herpetic neuralgia. 
Among the 19 cases of post herpetic neuralgia, 14 were male 
and 5 patients were female. 
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Table - 9 : Age group wise occurrence of PHN 
S.No Age Male Female Total % Associated 
Disease 
1. 10-20 years 0 1 1 5.2%  
2. 21-30 years 1 0 1 5.2% HIV-I 
3. 31-40 years 0 0 0   
4. 41-50 years 4 2 6 31.5% Bronchial -1 
Asthma 
5. 51-60 years 3 0 3 15.7%  
6. 61-70 years 5 2 7 36.8% Diabetes - 1 
7. 71-80 years 0 0 0   
8. 81 & above 1 0 1 5.2%  
  14 5 19 100%  
The highest prevalence of PHN (36.8%) was noted in the age 
group of 61 to 70 years which was followed by 31.5% in the age 
group of 41 to 50 years and 15.7% in the age group of 51 to 60 years. 
Minimum number of cases were observed in the groups of 10 
to 20 years and 21 to 30 years of age with one case (5.2%) in each 
age group. 
PHN was seen in a patient with HIV infection in one case, 
bronchial asthma 1 case and diabetes - 1 case. 
 
62
Out of 19 cases of post herpetic neuralgia, 4 cases had 
spasmodic shooting pain, 2 cases had lancinating pain and the 
remaining 13 cases had burning type of pain. 
Among the 19 cases of PHN, 12 cases were given 
T.Carbamazepine and 7 cases were given T. Amitriptyline. 
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DISCUSSION 
Herpes zoster is common among immunocompromised 
persons, so the elderly are at particular risk because 
immunocompetence declines with age. Whitley et al91 reported that 
zoster affects 20% of general population during their life time, 
especially in elderly. This study of hundred patients with herpes 
zoster revealed that the majority of the patients affected were 
adults in the second (25%), third (14%) and fourth (24%) decades. 
More than two thirds (73%) of the reported cases occurred in 
individuals below the age of 50 and the remaining 27% of affected 
cases were above 50 years of age. This is in contrast to the 
observation made earlier in other studies25 where in more than two 
third of cases where in the age group above 50 years with highest 
incidence among individuals in the sixth to eighth decades of life. 
Total number of cases in childhood and adolescence age 
group were ten (10) in number. 
In this study male: female ratio was 2.5:1 which is in contrast 
with the Western Studies92 where both male and female were 
equally affected. 
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Prodromal symptoms were in a higher rate (85%) in this 
study. In majority of cases dermatomal pain was the commonest 
prodromal symptom. This is in contrast to the lower incidence of 
prodromal symptoms (5%) observed in younger age groups, in 
various other studies25. 
In this study majority of the cases (74%) presented between 2 
to 5 days and the remaining 26% of cases presented between 6 to 8 
days and above, which is similar to the study report given in 
western literature25. 
Most common presenting symptom in this study was pain in 
99% of cases and vesiculation was the next common presenting 
complaint in 98% of cases which is similar to various study 
reports25,93.  
Constitutional symptoms were noted in 75% of cases in this 
study and majority of cases were in younger age group. 
This is in contrast to the lower incidence of prodromal 
symptoms (5%) observed, especially in younger age groups, in 
various other studies25. 
In this study 97% of cases had classical herpes zoster in 
dermatomal pattern25 and 3% of cases had crusting and erosions. 
Thoracic dermatome was the most common dermatome involved 
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(60%) in this study followed by cervical dermatome in 9% of cases, 
ophthalmic zoster in 8% of cases and lumbar dermatome in 7% of 
cases, in accordance with the literature reports33. The least 
common dermatome involved was sacral segment. 
Out of 100 cases 97% of cases had localised involvement with 
grouped vesicles and 1% of case had multidermatomal involvement, 
and the remaining 2% of cases had cutaneous dissemination in 
addition to the classical dermatomal distribution. Multidermatomal 
and disseminated zoster was more frequent in males than females 
Multidermational zoster case with Ramsay Hunt syndrome was 
reported with malignancy. 
One case of disseminated zoster was associated with HIV 
infection. Lymph node enlargement was noted in 95% of cases. 
Thirty six cases were having one or more suspected 
provocative factors. Out of 36 cases most common risk factor seen 
was HIV infection in 16 cases (44.4%) followed by diabetes in 7 
cases (19.4%) and 5 cases (13.8%) on steroid therapy. Malignancy, 
radiotherapy, Hansen’s disease, tuberculosis, renal transplantation, 
physical stress of parturition and pregnancy were also noted as 
provocative factors one case each. Depressed cell medicated 
immunity associated with the above conditions, as described in 
literature25 could be the possible factors for the development of zoster. 
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Past history of chicken pox was given by 90% of cases. The 
remaining 10% of cases were either not aware of or not had chicken pox.  
Systemic diseases seen in association with herpes zoster were 
diabetes mellitus 7 cases, hypertension 6 cases, SLE 3 cases, 
bronchial asthma 2 cases, tuberculosis 1 case, hepatitis B infection  
1 case and chronic renal failure 1 case. 
Few cutaneous diseases seen in herpes zoster patients in this 
study and those cases were acne (1 case), tinea versicolor (2 cases), 
seborrheic dermatitis (2 cases), SLE (3 cases), insect bite allergy (2 
cases) and Hansen’s disease, cellulitis, oral candidiosis, tinea cruris 
and intertrigo, one case each. 
Most of these cases were associated with 
immunosuppression. 
Period of time taken for resolution or healing of the lesions, 
in this study, ranged from 2 to 4 weeks, as described in literature33. 
Tzanck smear was positive in 95% of cases with vesicular 
lesions and it was negative in 5% of cases with erosions, crusting 
and ulceration correlates well with that of literature reports25. 
Complete hemogram was normal in 68% of cases in this study. This 
is in contrast to the literature reports, where in normal complete 
hemogram results are reported in zoster patients93. Raised ESR was 
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noted in 20 patients, increased eosinophil and neutrophil count 
noted in 6 patients each and decreased hemoglobin value was noted 
in 4 patients. 
Blood sugar was elevated in above normal value in 7 patients. 
Urine routine examination was normal in almost all patients (98%). 
Urine examination showed reducing sugar in 2 patients (2%). 
In this study, 16% cases of the 100 patients who were tested 
for HIV were sero positive. Among the 16% of cases of HIV 
positivity, herpes zoster was the presenting disease for HIV 
infection in 6% cases, and 10% cases developed herpes zoster 
during the course of HIV infection. Results of this study showed 
higher incidence of herpes zoster in HIV infection. Recurrence of 
zoster lesions in HIV positive patients were not observed in this 
study. 
Skin biopsy showed histopathological features as described in 
literature25, 11. 
ECG was taken for all cases with lesions involving left upper 
thoracic dermatomes and no abnormality was detected.  
Post herpetic neuralgia was the commonest complication 
noted in 19 patients (47.5%) followed by secondary bacterial 
infection in 15 cases (37.5%), scarring in 5 cases (12.5%) and motor 
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zoster (facial palsy) in 1 case (2.5%). Post herpetic neuralgia is the 
commonest complication reported in the literature33. 
In accordance to the literature reports33, the incidence of post 
herpetic neuralgia increased with increasing age in this study. 
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CONCLUSION 
1. In this study herpes zoster mainly occurred in second, 
third and fourth decades of life. More than two third 
(73%) of cases occurred in individuals below the age of 
50 years. 
2. Male preponderance in incidence was found with the 
sex ratio of 2.5:1 
3. Prodromal symptoms were present in 85% of patients 
and dermatomal pain was the commonest prodromal 
symptom. 
4. Most common presenting symptom was pain in 99% of 
cases, followed by vesiculation in 98% of cases. 
5. Constitutional symptoms were noted in 75% of cases 
and majority of cases were in younger age group. 
6. Thoracic dermatome was the most common dermatome 
involved and sacral segment was the least common 
dermatome affected. 
7. HIV infection was present in 16% of total cases. Out of 
this, 10% of cases were already diagnosed as HIV 
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positive and developed herpes zoster during the course 
of HIV disease and herpes zoster was the presenting 
disease of HIV infection in 6% of cases. This indicates 
the importance of HIV testing in all patients presenting 
with herpes zoster, especially in patients below the age 
of 50 years. 
8. No significant association of herpes zoster was found 
with any other skin disorder in this study. 
9. The most common systemic diseases noted were 
diabetes mellitus, hypertension and are considered 
coincidental. Other systemic diseases associated with 
herpes zoster were SLE bronchial asthma, tuberculosis, 
chronic renal failure and hepatitis B infection. Steroid 
therapy given for certain systemic disorders and 
decreased CMI acted as provocative factor for herpes 
zoster. 
10. Duration of time taken for resolution or healing of the 
lesions, ranged from 2 to 4 weeks. 
11. Post herpetic neuralgia was the commonest 
complication (47.5%) and the incidence of PHN 
increased with increasing age. The other complications 
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noted were secondary bacterial infection, scarring and 
motor zoster (facial palsy). 
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PROFORMA 
Name :     Age :   Sex : 
Hospital No.        Case No. 
: 
Occupation :        Address : 
PRESENTING COMPLAINTS: 
H/O. PRESENT ILLNESS 
H/o. vesicles - onset, progression, duration 
H/o. Pain and nature of pain 
H/o. Paraesthesia 
H/o. Fever, Malaise 
H/o. Itching, tingling, numbness over the involved site 
H/o. Difficulty in swallowing 
H/o. Pain & Photophobia in eye 
H/o. Watering in eye 
H/o. Headache 
H/o. Toothache (Oro facial Zoster) 
H/o. Otalgia 
H/o. Tinnitus and giddiness 
H/o. Difficulty in urination / defecation 
H/o. Treatment  
H/o. Diabetes 
H/o. Malignancy 
PAST HISTORY 
H/o. Varicella 
H/o. Diabetes, TB 
H/o. Recurrent Zoster 
TREATMENT HISTORY 
H/o. Treatment for malignancy 
H/o. Steroid therapy / Other immunosuppressive drug therapy 
H/o. Treatment for HIV 
H/o. Treatment for Diabetes 
H/o. Radiotherapy 
FAMILY HISTORY 
H/o. Varicella in any other family members (for contact exacerbation) 
PERSONAL HISTORY 
H/o. Alcoholism / Smoking  
H/o. Sexual exposure 
MENSTRUAL HISTORY 
GENERAL EXAMINATION 
Anemia, Jaundice, Edema, Lymphadenopathy (Regional / Generalised) 
SYSTEMIC EXAMINATION 
CVS :    RS: 
Abd :    CNS: 
DERMATOLOGICAL EXAMINATION 
SKIN 
• Site of Lesion   Dermatome involved 
• Distribution of Vesicles Grouped or Scattered 
• Stages of Vesicles  Erythema, Papules, Vesicles, Crust 
• Hyperaesthesia 
• Complications:  
Secondary infection, Ulceration, Post inflammatory hypo/hyper 
pigmentation, Scarring  
• Mucosa  
• Hair and Nail    
• Palms and Soles 
INVESTIGATIONS: 
Blood  - TC,  DC, ESR, Hb% 
Blood - Sugar 
  Urea 
Serum - Creatinine 
Urine - Albumin 
  Sugar 
  Deposit 
Tzanck Smear -  
ECG (When it is needed) - 
ELISA -  
Specialist opinion (for selected cases) 
Biopsy (If necessary) - 
TREATMENT 
T. Aciclovir as per the requirement 
Other supportive measures 
FOLLOW UP: (For 3 Months) 
• PHN 
• Other Complications 
ACRONYMS 
 
Sl. 
 No. 
Acronyms Expansion 
1. PHN  Post Herpetic Neuralgia 
2. HIV Human Immuno Deficiency Virus Infection 
3. N Normal 
4. POS Positive 
5. Neg Negative 
6. Zinc Cal Lotion Zinc Oxide Calmine Lotion 
7. ACV Aciclovir 
8. SSD Silver Sulphadiazine Cream 
9. Carbamaz Carbamazepine 
10. ESR Erythrocyte Sedimentation Rate 
11. ELISA Enzyme Linked Immuno Sorbent Assay 
12. Bd Blood 
13. RFT Renal Function Test 
14. ECG Electro Cardiogram 
15. CRF Chronic Renal Failure 
16. ART Anti Retroviral Therapy 
17. HT Hypertension 
18. SLE Systemic Lupus Erythematosus 
19. Hb Haemoglobin 
20. Seb Derm Seborrheic Dermatitis 
21. IBA Insect Bite Allergy 
22. TB Tuberculosis 
23. ATT Anti Tuberculosis Therapy 
Sl. 
 No. 
Acronyms Expansion 
24. BL Borderline Lepromatous Leprosy 
25. LL Lepromatous Leprosy 
26. MB - MDT Multi bacillary - Multi Drug Therapy 
27. ANC Antenatal Case 
28. HBV Hepatitis B Virus Infection 
29. RT Radiotherapy 
30. Ca Cx Carcinoma Cervix 
31. Rt Right 
32. Lt Left 
33. TV Tinea Versicolor 
34. VZV Varicella Zoster Virus 
 
